Previous 10 | Next 10 |
AnaptysBio (ANAB) rose 8.4% after a report that the biotech company received a takeover offer.AnaptysBio is working with an investment bank to solicit interest from other parties after the approach, according to a StreetInsider report.Developing story ... For further details see: A...
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
AnaptysBio (ANAB): Q1 GAAP EPS of -$0.66 beats by $0.03.Revenue of $11.25M (-25.0% Y/Y) beats by $1.86M."AnaptysBio expects its net cash burn in 2021 will be close to $100 million. We anticipate that our cash, cash equivalents and anticipated revenues will fund our current operating plan at l...
Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021 JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with GlaxoSmithKline (GSK), was approved for endometrial cancer in the US and EU during Q2 202...
Only a day after its regulatory approval in the U.S., GlaxoSmithKline ([[GSK]] -0.1%) announces that the European Commission has granted the conditional marketing authorization for Jemperli (dostarlimab) for endometrial cancer in a second-line setting.The PD-1-blocking antibody is now i...
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to Obtain Regulatory Approval in Europe $10MM Milestone Payment Earned by AnaptysBio Upo...
AnaptysBio (ANAB) is up ~3.0% in the pre-market after announcing a $20M worth milestone payment earned following the FDA approval of Jemperli (dostarlimab-gxly) in the treatment of endometrial cancer.Under the accelerated approval, yesterday, the FDA authorized the marketi...
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to Obtain FDA Approval $20MM Milestone Payment Earned by AnaptysBio Upon FDA Approval; A...
The FDA has approved Jemperli (dostarlimab) for the treatment of adults with recurrent or advanced endometrial cancer in a second-line setting, according to the regulator’s website.AnaptysBio ([[ANAB]] +2.6%) and GlaxoSmithKline ([[GSK]] -1.4%) have a collaboration agreement for c...
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announc...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...